Displaying all 2 publications

Abstract:
Sort:
  1. Occlusal device therapy for sleep bruxism: Analysis of educational value, clarity, reliability, understandability, and actionability of information of content on YouTube
    Thong TX, Wai JMW, Nimbalkar S, Patil PG
    J Prosthet Dent, 2024 Dec 03.
    PMID: 39632229 DOI: 10.1016/j.prosdent.2024.10.022
    STATEMENT OF PROBLEM: Sleep bruxism, characterized by teeth grinding during sleep, is often managed with an occlusal device. Despite the abundance of YouTube videos discussing occlusal device therapy, their educational quality remains unclear.

    PURPOSE: The purpose of this process-based audit was to assess the educational value (EV), clarity (COI), reliability (ROI), understandability (UOI), and actionability (AOI) of information regarding occlusal device therapy for sleep bruxism in YouTube videos provided by dental professionals.

    MATERIAL AND METHODS: YouTube was searched systematically using 4 search terms. A total of 19 videos were identified using predetermined criteria. EV was assessed using a 4-point scoring system across 10 predetermined domains. A 3-point scoring system was applied to evaluate COI. Journal of American Medical Association (JAMA) Benchmark Criteria was applied to evaluate ROI. Patient Education Materials Assessment Tool for audio-visual material (PEMAT-A/V) was used to determine UOI and AOI. Descriptive statistics, interrater and intrarater reliability tests were conducted using a statistical software program.

    RESULTS: Most videos had been uploaded by general dental practitioners (95%) followed by orthodontists (5%). The mean number of reported domains was 4.68 ±2.73 (out of 10), with the highest scoring domain being "Indications of occlusal device" (1.24 ±0.87), and the lowest being "Cost of occlusal device" (0.00 ±0.00). Overall, the EV score per video was 5.61 ±5.10 (out of 30), while the COI score was 0.55 ±0.50 (out of 2). The ROI averaged 1.95 ±0.40 (out of 4), with "Attribution" scoring lowest (0.026 ±0.11) and "Currency" highest (1). Overall, the videos had a mean understandability of 66.6% and actionability of 45.6%.

    CONCLUSIONS: Videos uploaded by dental professionals lack sufficient educational value pertaining to the cost of occlusal devices. The videos demonstrated low reliability regarding the credibility of sources and poor understandability and actionability.

  2. Fulltext Amoxicillin/Clavulanic Acid for the Treatment of Odontogenic Infections: A Randomised Study Comparing Efficacy and Tolerability versus Clindamycin
    Tancawan AL, Pato MN, Abidin KZ, Asari AS, Thong TX, Kochhar P, et al.
    Int J Dent, 2015;2015:472470.
    PMID: 26300919 DOI: 10.1155/2015/472470
    Background. Treatment of odontogenic infections includes surgical drainage and adjunctive antibiotics. This study was designed to generate efficacy and safety data to support twice daily dosing of amoxicillin/clavulanic acid compared to clindamycin in odontogenic infections. Methods. This was a phase IV, randomised, observer blind study; 472 subjects were randomised to receive amoxicillin/clavulanic acid (875 mg/125 mg BID, n = 235) or clindamycin (150 mg QID, n = 237) for 5 or 7 days based on clinical response. The primary endpoint was percentage of subjects achieving clinical success (composite measure of pain, swelling, fever, and additional antimicrobial therapy required) at the end of treatment. Results. The upper limit of two-sided 95% confidence interval for the treatment difference between the study arms (7.7%) was within protocol specified noninferiority margin of 10%, thus demonstrating noninferiority of amoxicillin/clavulanic acid to clindamycin. Secondary efficacy results showed a higher clinical success rate at Day 5 in the amoxicillin/clavulanic acid arm. Most adverse events (raised liver enzymes, diarrhoea, and headache) were similar across both arms and were of mild to moderate intensity. Conclusion. Amoxicillin/clavulanic acid was comparable to clindamycin in achieving clinical success (88.2% versus 89.7%) in acute odontogenic infections and the safety profile was consistent with the known side effects of both drugs. Trial Registration. This trial is registered with Clinicaltrials.gov identifier: NCT02141217.
Related Terms
    Try searching for something
Filters
Contact Us

Please provide feedback to Administrator (afdal@afpm.org.my)

External Links